Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results


Creative Commons License

ADIYAMAN S. C., ALACACIOĞLU İ., Danyeli A. E., Turkyilmaz D., Sevindik O. G., DEMİRKAN F., ...More

TURKISH JOURNAL OF HEMATOLOGY, vol.36, no.2, pp.81-87, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.4274/tjh.galenos.2019.2018.0219
  • Journal Name: TURKISH JOURNAL OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.81-87
  • Keywords: Lymphoid cell neoplasms, B-Cell neoplasms, Lymphomas, Non-Hodgkin lymphoma, NON-HODGKINS-LYMPHOMA, GERIATRIC ONCOLOGY, CHOP CHEMOTHERAPY, DES LYMPHOMES, IMPACT, RITUXIMAB, CLASSIFICATION, SUBTYPE, TRIAL
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objective: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). The treatment of older NHL patients has always been a struggle; however, treatment statistics have begun showing favorable results similar to those of younger DLBCL patients thanks to newer treatment protocols. Here, we analyze the progress of our own elderly DLBCL patients who were followed between 2000 and 2016 in our center.